title: The effect of pH on the buccal and sublingual absorption of captopril.
abstract: The effect of pH on the buccal and sublingual absorption of captopril was evaluated using in vitro techniques and human studies. Partitioning of captopril into n-octanol was lowest over the pH range 5 to 8 and highest at pH values 3, 4 and 9. Using the buccal absorption technique, the partitioning of captopril (2 mg) was examined in six healthy male volunteers from buffered solutions (pH 3, 4, 5, 6, 7, 8, and 9). Lowest buccal partitioning occurred at pH 3 while maximal buccal partitioning occurred at pH 7. These data clearly indicated that the buccal absorption of captopril pharmacokinetic and pharmacodynamic parameters were determined after administration of buffered sublingual captopril (pH 7, optimal hP for absorption as determined from the buccal partitioning data) and unbuffered sublingual captopril. The study was performed in eight healthy volunteers in a randomised single-blind cross-over fashion. The tmax for captopril was found to be approximately 11 minutes earlier after buffered versus unbuffered sublingual administration and AUC0-30 min increased by approximately 30% in the case of buffered captopril. Cpmas, AUC0-180 min and relative bioavailability did not differ between the buffered and unbuffered administration. Pharmacodynamic parameters (BP, heart rate and plasma renin activity) did not differ significantly between buffered and unbuffered sublingual administration. The increased rate of captopril absorption after buffered sublingual administration was small and is likely to offer little therapeutic advantage over conventional sublingual formulation.
authors.affiliation: Pharmacy Practice Research Group, School of Pharmacy, Queen's University of Belfast, UK.
authors.forename: J C
authors.initials: JC
authors.lastname: McElnay
authors.forename: T A
authors.initials: TA
authors.lastname: al-Furaih
authors.forename: C M
authors.initials: CM
authors.lastname: Hughes
authors.forename: M G
authors.initials: MG
authors.lastname: Scott
authors.forename: J S
authors.initials: JS
authors.lastname: Elborn
authors.forename: D P
authors.initials: DP
authors.lastname: Nicholls
mesh_terms: D020003:1-Octanol; D000042:Absorption; D000328:Adult; D000959:Antihypertensive Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D002021:Buffers; D002216:Captopril / Q000737:chemistry / Q000493:pharmacokinetics*; D002610:Cheek; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D018592:Cross-Over Studies; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009060:Mouth Floor; D009061:Mouth Mucosa / Q000378:metabolism*; D000442:Octanols / Q000737:chemistry; D016037:Single-Blind Method; D014867:Water / Q000737:chemistry
chemical_list: D000959:Antihypertensive Agents; D002021:Buffers; D000442:Octanols; D014867:Water; D002216:Captopril; D020003:1-Octanol